Characterization of autologous cell sources for alternatives to aortic valvular interstitial cells in tissue engineered heart valves
The gold standard treatment for patients with AVD is surgical replacement of the aortic valve with either mechanical or fixed tissue prostheses. These implants have a limited lifespan and are associated with serious adverse events. Patient autologous tissue engineered heart valves (TEHVs) offer a so...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
2016
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1993/31804 |